News & Events
- Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research
- OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research
- OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
Featured Articles
Designed to Arm the Immune System to Fight Cancer
We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.
Clinical Pipeline
Our core technology platform continues to advance through clinical trials for various cancers
Learn More
Technology
Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer
Learn More
Partnerships
We have a track record of establishing, operating and evolving high-performance partnerships globally
Learn More
